BCL2 and diffuse large B-cell lymphoma: Our main objectives were to (i) assess the effect of Bcl-2 protein expression on both overall and progression-free survival in non-GCB DLBCL patients treated with rituximab-based immunochemotherapy, and (ii) identify any differences in the response to treatment among those highly expressing Bcl-2 when compared to those who do not.